Discontinued — last reported Q4 '24
Applovin Corporation CapEx remained flat by 0.0% to $1.19M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 389.3%, from $244.00K to $1.19M. Over 3 years (FY 2021 to FY 2024), CapEx shows an upward trend with a 50.9% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $532.00K | $309.00K | $428.00K | $285.00K | $115.00K | $221.00K | $41.00K | $70.00K | $3.75M | $183.00K | $244.00K | $1.19M | $1.19M | $1.19M | $1.19M |
| QoQ Change | — | -41.9% | +38.5% | -33.4% | -59.6% | +92.2% | -81.4% | +70.7% | >999% | -95.1% | +33.3% | +389.3% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | -78.4% | -28.5% | -90.4% | -75.4% | >999% | -17.2% | +495.1% | >999% | -68.2% | +552.5% | +389.3% |